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Abstract 5 
Tramadol concentrations and analgesic effect are dependent on the CYP2D6 enzymatic 6 
activity. It is well known that some genetic polymorphisms are responsible for the 7 
variability in the expression of this enzyme and in the individual drug response. The 8 
detection of allelic variants described as non-functional can be useful to explain some 9 
circumstances of death in the study of post-mortem cases with tramadol. A Sanger 10 
sequencing methodology was developed for the detection of genetic variants that cause 11 
absent or reduced CYP2D6 activity, such as *3, *4, *6, *8, *10 and *12 alleles. This 12 
methodology, as well as the GC/MS method for the detection and quantification of 13 
tramadol and its main metabolites in blood samples was fully validated in accordance 14 
with international guidelines. Both methodologies were successfully applied to 100 15 
post-mortem blood samples and the relation between toxicological and genetic results 16 
evaluated. Tramadol metabolism, expressed as its metabolites concentration ratio (N-17 
desmethyltramadol/O-desmethyltramadol), has been shown to be correlated with the 18 
poor-metabolizer phenotype based on genetic characterization. It was also demonstrated 19 
the importance of enzyme inhibitors identification in toxicological analysis. According 20 
to our knowledge, this is the first study where a CYP2D6 sequencing methodology is 21 
validated and applied to post-mortem samples, in Portugal. The developed methodology 22 
allows the data collection of post-mortem cases, which is of primordial importance to 23 
enhance the application of these genetic tools to forensic toxicology and pathology. 24 
 25 
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 30 
1. Introduction 31 
Tramadol is a centrally acting opioid analgesic commonly prescribed for treatment of 32 
postoperative, dental, cancer, neuropathic and acute musculoskeletal pain control , with 33 
high clinical efficacy, low incidence of adverse effects and low abuse potential. 34 
Tramadol is administrated in a racemic mixture and undergoes extensive phase I and II 35 
metabolization to 23 metabolites, mostly excreted in the urine. The main metabolites 36 
resulting from the phase I metabolization are O-desmethyltramadol (ODT), catalyzed by 37 
CYP2D6 enzyme, and N-desmethyltramadol (NDT), catalyzed by CYP3A4 and 38 
CYP2B6 enzymes. Tramadol acts as a norepinephrine and serotonergic re-uptake 39 
inhibitor, possesses low affinity for µ opioid receptors and no affinity for δ or κ opioid 40 
receptors. The main opioid analgesic effect is attributed to ODT because it has 41 
approximately 300 times more affinity to -opioid receptors than the parent compound 42 
[1–3].  43 
Post-mortem concentrations of tramadol are difficult to compare with reference values 44 
of therapeutic and toxic levels. There are variables as post-mortem redistribution, 45 
variations on the sample collection site and the time between the administration and the 46 
death that can influence the post-mortem concentrations. Tolerance in chronic users, 47 
drug interactions and individual genetic factors are also specific aspects of each case 48 
that must be considered in the interpretation of toxicological results. Genotyping can be 49 
a useful tool to post-mortem toxicology to explain some unexpected concentrations of 50 
tramadol and parent/metabolite ratios. 51 
1.1. CYP2D6 52 
CYP2D6 enzyme is coded by a gene with the same name that is located on the human 53 
chromosome 22 (22q13.1) and is part of a cluster with 2 pseudogenes, CYP2D7 and 54 
CYP2D8. These three genes have a high genetic homology but can be distinguished by 55 
some well characterized sequence variants that are responsible for the incapacity of the 56 
pseudogenes to produce a functional enzyme [4]. CYP2D6 gene is highly polymorphic 57 
and more than 20 allelic variants have been already correlated with the enzyme 58 
inactivation, usually called null alleles (http://www.cypalleles.ki.se/cyp2d6.htm), some 59 
of them with high prevalence in Caucasian population. When these genetic variants are 60 
present the metabolic activity is compromised. The characteristics of CYP2D6 gene 61 
locus, possible genotypes and phenotypes, as well as the difficulties of the genetic 62 
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analysis and interpretation were extensively reviewed by Andrea Gaedigk in 2013 [4]. 63 
1.2. Genotype and metabolism 64 
The metabolic capability can be distinguished in four different groups: poor (PM), 65 
intermediate (IM), extensive (EM) and ultra-rapid metabolizers (UM). Poor 66 
metabolizers have very low metabolic capacity and higher metabolic ratios. Genetically 67 
they are characterized by the presence of 2 null alleles and 5 to 10% of the European 68 
population are considered to be PM [5]. The alleles CYP2D6 *3, *4, *5 and *6 are 69 
responsible for 93-98% of the PM [6]. The relationship between CYP2D6 genetic 70 
variation and enzymatic activity has already been studied by many authors and recently 71 
reviewed by Zanger and Schwab [5]. 72 
In tramadol positive cases, the relation between low metabolism phenotype and PM 73 
genotype of CYP2D6 has already been demonstrated by several studies: PM have a 74 
lower concentration of ODT, the main active metabolite, reducing the opioid analgesic 75 
effect as well as the opioid related adverse effects [2,7–13]. The half-life and 76 
concentration of tramadol can be higher in PMs [11] and the alternative metabolic ways 77 
can be stimulated. CYP2B6 and CYP3A4 enzymes catalyze the biotransformation of 78 
tramadol to N-desmethyltramadol (NDT), an inactive metabolite. The inhibition of the 79 
CYP2D6 metabolism can conduce to an increment of the concentration of NDT 80 
[1,7,10].  81 
High blood concentrations of tramadol, due to accumulation or to increasing dosage, 82 
can lead to adverse reactions, not directly related with the opioid depression of the 83 
central nervous system, but specially with the inhibition of serotonin and 84 
norepinephrine reuptake [1]. 85 
1.3. Forensic application 86 
Forensic pharmacogenetics is a relatively new and growing area of research [9,14–16]. 87 
The application of genotyping methodology to post-mortem forensic cases is dependent 88 
on the level of the DNA degradation, the existence of reliable methodologies that can be 89 
applied to routine analysis and on the gene characteristics. The interpretation of the 90 
results depends on the knowledge based on scientific research with statistical coverage, 91 
reason why further studies and the compilation of post-mortem data are needed to fully 92 
understand the relation between toxicological and genetic results. This information is 93 
important to enable the use of genotyping in the evaluation of some cases, specially 94 
when the concentration of drugs and metabolites can be considered suspect of an acute 95 
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intoxication. 96 
 97 
To aid the interpretation of unexpected high concentrations of tramadol in post-mortem 98 
cases, it is important to have a method capable to detect genetic variants of CYP2D6 99 
responsible for the enzyme inactivation. The purpose of this study was to develop and 100 
validate a Sanger sequencing method to detect the more prevalent null variants in post-101 
mortem blood samples, using the technology usually existent in the forensic genetics 102 
laboratories without further costs.  103 
 104 
2. Materials and methods 105 
2.1.Samples 106 
100 post-mortem peripherical blood samples, positive for tramadol, were selected from 107 
forensic toxicological cases that were analyzed between 2012 and 2015 in the south 108 
branch of the National Institute of Legal Medicine and Forensic Science (INMLCF), in 109 
Portugal. In the selected cases, 56 were male and the mean age of the subjects was 65 110 
years old (range: 30 to 93). The probable cause of death mentioned in the toxicological 111 
request was: violent traumatism (34 cases); intoxication (10 cases); natural death (16 112 
cases) and unknown (40 cases). 113 
2.2.CYP2D6 genetic analysis 114 
Blood spots were collected in Whatman
®
 FTA cards according to manufacturer’s 115 
recommendations. DNA was extracted using Chelex100
®
 method [17] and quantified by 116 
Real-Time PCR using the Quantifiler
®
 Trio DNA Quantification kit from Applied 117 
Biosystems (AB) [18], according to the standard protocol . 118 
The PCR amplification method was modified and optimized from Levo et al [7] and 119 
Hersberger et al [6]. For each sample, three fragments of 200bp, 437bp and 736bp were 120 
directly amplified, to detect the main null alleles CYP2D6 *3 (2549delA); CYP2D6 *4 121 
(100C>T and 1846G>A) and CYP2D6 *6 (1707delT), but also other variants located in 122 
these fragments, such as CYP2D6 *8 (1758G>T), *10 (100C>T), *12 (124 G>A), *14 123 
(1758G>A), *15 (137_138insT), *40 (1863_1864 ins), *43 (77G>A), *44 (82C>T), *47 124 
(73C>T), *49 (1611T>A) and *50 (1720A>C). PCR was prepared to a final volume of 125 
25 L, using Multiplex PCR Master Mix 2x (QIAGEN); dimethylsulfoxide 5% 126 
(DMSO); 200nM of primers and approximately 5 ng of DNA. Thermocycling 127 
conditions were adjusted to obtain the better results for each fragment (Table 1). After 128 
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purification with ExoSAP-IT
®
 (Affymetrix) the amplification was confirmed by SDS-129 
PAGE Electrophoresis with Silver Staining in a Phastsystem (GE Healthcare).  130 
The modified Sanger sequencing reaction was performed with BigDye Terminator v.3.1 131 
Cycle Sequencing Kit of AB, using 4 μL of Better Buffer (Microzone); DMSO; 500nM 132 
of each of the PCR primers and 1μL of amplified template, to a final volume of 10 L. 133 
Thermocycling conditions used are in Table 1. After purification with the BigDye 134 
XTerminator Purification Kit (AB), the sequencing products were analyzed by capillary 135 
electrophoresis in a Genetic Analyzer 3130 of AB.  136 
 137 
Table 1. Thermocycling conditions for the PCR and sequencing methods. 138 
PCR [-173 to 264] [1299 to 2035] [2369 to 2569] 
Initial denaturation 95ºC/15 min 95ºC/15 min 95ºC/15 min 
Cycles 40 40 35 
denaturation 94ºC/30s 94ºC/30s 94ºC/30s 
annealing 55ºC/30s 55ºC/30s 57ºC/30s 
extension 72ºC/30s 72ºC/30s 72ºC/30s 
Final extension 72ºC/7 min 72ºC/7 min 72ºC/7 min 
Sequencing    
Initial denaturation 95ºC/3 min 95ºC/3 min 95ºC/3 min 
Cycles 35 35 35 
denaturation 95ºC/20s 95ºC/20s 95ºC/20s 
annealing 55ºC/20s 55ºC/20s 57ºC/20s 
 139 
The results were verified using the Sequencing Analysis v.5.2 software. The sequence 140 
alignment was done according to the Human Cytochrome P450 Allele Nomenclature 141 
Committee (http://www.cypalleles.ki.se) and the allelic variants were detected 142 
comparing the sequences obtained with the reference sequence (entry M33388.1 at 143 
Genbank) using SeqScape v.3 software.  144 
2.3.Validation of the genetic method  145 
The method was validated according to the general SWGDAM guidelines, with a 146 
special approach for Sanger sequencing methodology [21], and fulfilling the ENFSI 147 
recommended minimum criteria for the following parameters: specificity, accuracy, 148 
repeatability, reproducibility and sensitivity [19–23].  149 
Reference materials were selected from the Coriell Cell Repositories (National Institute 150 
of General Medical Sciences) based on genotypic characterization with the more 151 
prevalent variants (ref: NA17226; NA17280 and NA17300) that included: 100C>T; 152 
1707 del T; 1846G>A, 2549delA [24]. The genotypes were correctly assessed and the 153 
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peak balance ratios of heterozygote alleles were above 60%. These samples were used 154 
as positive controls in the analysis. 155 
All the sequences obtained were well aligned with the reference sequence. NCBI’s 156 
BLAST (basic local alignment search tool) analysis for sequence similarity was also 157 
used in the primers and in the sequences of 3 different samples to evaluate the 158 
specificity and to check for homology to other genes or pseudogenes that may interfere 159 
with the analysis. The search was made using “Standard Nucleotide BLAST”, in the 160 
“nucleotide collection nr/nt; human (taxid:9606)”, with Megablast [29]. The 18 161 
sequences verified had matches of 99-100% with the “Homo sapiens CYP2D6 162 
(CYP2D6) gene, complete cds, Sequence ID: gb|JF307778.1|Length: 6587”, depending 163 
on the variants of each sample. The search using NCBI Genomes (chromosome) 164 
database only match with the Homo sapiens Chromossome 22 Primary Assembly with 165 
100% identity. 166 
The Limit of Detection was determined by performing dilution experiments of a high-167 
quality genomic DNA with a known concentration for the following final 168 
concentrations: 10, 1, 0.5, 0.1, 0.05, 0.01ng/uL. Signal/Noise and variant identification 169 
were the parameters evaluated. The minimum concentration at which was possible to 170 
correctly identify the genotype in all the fragments was 0.1ng/L. The limits of 171 
detection of the smaller fragments were lower (0.05ng/L for the fragment with 437bp 172 
and 0.01ng/L for the fragment with 200bp), as expected. Nevertheless one postmortem 173 
sample with a DNA concentration of 0.06ng/L was successfully analyzed. 174 
The precision of the method was verified by repeatability and reproducibility 175 
experiments. To test the repeatability, three replicates of five samples with different 176 
genotypes were simultaneously analyzed, only varying the location in the thermocycling 177 
equipment and in the sequencing plate. With 2 sequences for each of the 3 fragments, a 178 
total of 30 replicates for each variant were evaluated, with 100% of success. 179 
To test the reproducibility, 15 samples were analyzed in three different days using the 180 
same technique, including the normal variables of the routine work in the lab, such as 181 
room temperature, reagents and equipments. With 2 sequences for each of the 3 182 
fragments, a total of 90 replicates in each variant were evaluated for quality and the 183 
correct variant identification. Results are given in the Table 2. 184 
 185 
Table 2. Reproducibility results of the genetic method validation 186 
7 
 
Allele *4, *10 *12 *6 *8 *4 *3 
Variant 100C>T 124G>A 1707delT 1758G>T 1846G>A 2549delA 
Day 1 15/15 15/15 15/15 15/15 14/14
2 15/15 
Day 2 15/15 15/15 14/14
1 14/141 14/141 15/15 
Day 3 15/15 15/15 15/15 15/15 15/15 15/15 
1
 – Failure in the amplification of the fragment. 2 – variant not sequenced. 187 
 188 
Most fragments were consistently amplified and sequenced, with only two failures: one 189 
in the sequence (day1) and one in the amplification (day2). The validation was made 190 
with routine post-mortem samples. The reported failures are in the larger fragment (with 191 
736bp) and the 2 samples with problems had a degradation index of 1.3 and 1.6, which 192 
are above 1 (the cut-off of the Quantifiler trio kit). 193 
The quality of the sequences was evaluated with the following criteria, as referenced in 194 
the Userguide for DNA Sequencing by Capillary Electrophoresis of the Applied 195 
Biosystems: Signal > 50, Signal/noise > 25 and Sample score between 20 and 50. 196 
Selecting 5 samples of one day of the reproducibility study, the values were calculated 197 
for 30 sequences and fulfilled the criteria: minimum Signal was 278, minimum 198 
signal/noise was 120 and minimum Sample score was 23.  199 
2.4. Toxicological analysis 200 
All the samples were analyzed by a general toxicological screening for pharmaceutical 201 
drugs as antidepressants, antipsychotics, opioids and others. The screening comprised 202 
the more prescribed compounds that are known to inhibit CYP2D6 enzymatic action, 203 
such as fluoxetine, paroxetine, sertraline, citalopram, haloperidol, methadone or 204 
ticlopidine [5,25]. The confirmation analysis of tramadol and its metabolites, O-205 
desmethyltramadol (ODT) and N-desmethyltramadol (NDT) was done in 500 L of 206 
peripherical blood stored at -10ºC in test tubes containing 1% of sodium fluoride.  207 
Blood samples were prepared by solid phase extraction using Oasis® HLB 3cc 60 mg 208 
cartridges (Waters) and GC-MS analysis was performed using an Agilent 6890 Gas 209 
Chromatograph equipped with a HP-5MS (30mx0.25mmx0.25mm) capillary column 210 
and a 5973 Mass Detector. The injector was set a 280ºC and the injection (1 µL) was 211 
made in split mode with 10:1 split ratio. The oven temperature was held at 150ºC for  1 212 
min, increased to 290ºC at a rate of 5ºC/min with a final hold time of 8 min. Data was 213 
acquired using selected ion monitoring mode (Error! Reference source not found.). 214 
Using a positive control prepared and analyzed simultaneously to the samples, the 215 
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identification criteria for positivity was: retention time within 2% or ±0.1 min; the 216 
presence of 3 ionic fragments per compound with S/N>3; the maximum allowed 217 
tolerances for the relative ion intensities were as required by the World Anti-Doping 218 
Agency [26]. 219 
2.5. Validation of the analytical method 220 
The method was fully validated according to international parameters. Experiments 221 
were conducted as described in the SWGTOX guidelines in terms of selectivity, 222 
interference studies, recovery, limit of detection, limit of quantification, linearity and 223 
calibration model, repeatability, reproducibility, accuracy and carryover [27,28]. All 224 
validation experiments were conducted using fortified samples of blank post-mortem 225 
blood using LGC and Lipomed standards.  226 
Selectivity was evaluated by analyzing 40 blank samples pooled. Two aliquots of each 227 
of the 10 pools were prepared: one was analyzed as blank and the other was spiked with 228 
all the analytes (100ng/mL). The chromatograms were compared, the identification 229 
criteria applied and the existence of interferences by matrix constituents was checked in 230 
the blank chromatograms. The method proved to be selective, fulfilled the criteria for all 231 
the samples and without interferences. For the recovery studies, six replicates were 232 
prepared at three concentrations (150, 500 e 850 ng/mL), three of them were spiked 233 
before extraction and the others 3 after. The internal standard was only added after the 234 
extraction procedure. The obtained peak area ratios were compared and the results are in 235 
the Table 3 . Five calibration curves were measured over a period of 15 days, using 236 
seven levels of spiked blood samples in the working range (between 50 and 237 
1000ng/mL) and three independent controls were prepared each day with the 238 
concentrations of 150, 500 and 850ng/mL. The calibration model was chosen as 239 
explained by Almeida et al [28] using as criteria the correlation coefficient higher than 240 
0.99 and the best calibrators’ accuracy (obtained by back calculating their 241 
concentrations). The method was linear over the working range using a weighting factor 242 
of 1/x2. Repeatability (within-day precision) was determined by analyzing six spiked 243 
samples at the low, medium and high concentration levels simultaneously. The accuracy 244 
and the precision were determined by the calculation of BIAS and the coefficient of 245 
variation (% CV), using the concentration obtained for the triplicates of controls (see 246 
Table 3). The limit of detection (LOD) was determined by the analysis of blood samples 247 
spiked with decreasing amounts of the analytes, being the lowest concentration that 248 
9 
 
fulfilled the identification criteria, with the signal/noise of all the peaks above 3, in the 249 
replicates (Table 3). The limit of quantitation (LOQ) was validated by analyzing six 250 
replicates of spiked samples with a concentration of 50ng/mL (the first point of the 251 
calibration curve) and verifying the coefficient of variation (<10%). Dilution of the 252 
sample was tested for 1:2 and 1:5 using 10 real samples, covering a concentration range 253 
between 50ng/mL to 5000ng/mL. The main results of the method validation are 254 
summarized in Table 3Error! Reference source not found.. 255 
 256 
Table 3. Summary of the main results obtained in the validation of the confirmation method for 257 
tramadol (TMD), N-demethyltramadol (NDT) and O-demethyltramadol (ODT). 258 
Compound 
RT 
(min) 
Ions 
(m/z) 
Mean 
Recovery 
LOD 
(ng/mL) 
CV BIAS 
NDT 12.1 58, 135, 263 88% 10 11% 2,0% 
ODT 12,5 249, 188, 135 95% 12.5 5,2% 1,0% 
TMD 13,4 58, 249, 121 93% 10 6,6% 0,7% 
 259 
2.6. Statistical analysis 260 
The genetic and toxicological results were graphically and statistically compared, using 261 
SPSS 17.0 software. The distribution of the results was tested for normality with 262 
Kolmogorov-Smirnova test and the hypothesis was rejected. Non-parametric tests were 263 
then used and the statistical differences between the medians of the genotype groups 264 
were calculated using the Mann–Whitney test with 95% of confidence interval.   265 
 266 
3. Results and discussion 267 
Post-mortem blood samples were studied searching for CYP2D6 genetic variants 268 
responsible for the enzyme inactivation, and the results obtained were then compared 269 
with the concentration of tramadol and its main metabolites: NDT and ODT. 270 
3.1. Genetic Results 271 
Among the 100 post-mortem samples analyzed in this study, amplification failed only in 272 
3 samples, which is comparable to other studies [9]. The DNA degradation was 273 
probably the main limitant factor as was demonstrated by the degradation index (DI) 274 
obtained with the Quantifiler trio kit. The degradation index of these samples was 4.2, 275 
6.5 and 12.1 whereas it was under 1.6 for all the others samples. 276 
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The sequencing methodology allowed the detection of 4 different alleles: CYP2D6*3 277 
(2549delA); CYP2D6*4 (100C>T and 1846G>A); CYP2D6*6 (1707delT) and 278 
CYP2D6*10 (100C>T). Sanger sequencing methodology can’t detect the copy number 279 
variation (CNV) of the gene, so it was not possible to identify the gene complete 280 
deletion (allele *5). Nevertheless, in cases with allele *5 the PM phenotype assignment 281 
is not necessarily compromised. In heterozigotes, this methodology will assign the 282 
individual as if he was homozygote for the other allele: if it is null, the individual will 283 
be designated as PM; if it’s functional, he will not. On the other hand, in *5/*5 284 
homozygotes, there will be no amplification product because there is no gene. So, when 285 
the amplification fails, there may be two main explanations: the low quantity or the 286 
degradation of the DNA in the sample, which can be evaluated using the degradation 287 
index given by Quantifiler trio kit; or maybe the individual is homozygote for the 288 
CYP2D6*5 allele, and this genotype should then be confirmed by a suitable method.  289 
 290 
The allele with the higher prevalence was CYP2D6 *4, with a frequency of 19.6%. The 291 
allele *10 was detected with a prevalence of 16,5%, which is higher than the expected 292 
based on large European population studies and according to CYP2D6 Allelic Variation 293 
Summary Table in http://www.cypalleles.ki.se/cyp2d6.htm [30,31] but is in accordance 294 
with a recent study for Portuguese population [32]. CYP2D6*10 isn’t a null allele but it 295 
can decrease the enzymatic activity and change the substrate specificity of the enzyme 296 
[13,33–35]. Only one allele *3 and one allele *6 have been detected. All the alleles that 297 
hadn’t any variant in the studied fragments were considered as wild type (WT). 298 
The genotype distribution is presented in the Table 4.   299 
 300 
Table 4. Genotype distribution for the 97 post-mortem samples. 301 
Genotype n Prevalence 
*4/*4 5 5,1% 
*3/*4 1 1,0% 
*4/*10 15 15,5% 
*10/*10 1 1,0% 
*4/WT 12 12,4% 
*6/WT 1 1,0% 
*10/WT 15 15,5% 
WT 47 48,5% 
 302 
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Six persons were predicted as poor metabolizers (PM) according to their CYP2D6 303 
genotype: 5 individuals were found as homozygotes for the allele *4 and one was 304 
heterozygote with one allele *3 and one allele *4.  305 
3.2. Toxicology results 306 
Among the post-mortem samples selected for this study, half presented tramadol 307 
concentration below 800 ng/mL, within the therapeutic range according to the published 308 
reference tables [36,37]. 27 of these cases had a negative result for at least one of the 309 
metabolites: 4 of them in the second group (tramadol concentrations above 800 ng/mL). 310 
Descriptive statistics of the concentration of tramadol and metabolites are presented in 311 
the Table 5.  312 
 313 
Table 5. Descriptive statistics for the concentration of tramadol (TMD), N-desmethyltramadol 314 
(NDT) and O-desmethyltramadol (ODT) in 100 post-mortem blood samples.  315 
TMD < 
800ng/mL 
TMD NDT ODT 
TMD > 
800ng/mL 
TMD NDT ODT 
mean 439 312 114 mean 3070 497 363 
median 421 77 75 median 1514 161 222 
max 789 464 482 max 34000* 3863 3127 
min 94 12 29 min 813 20 18 
* values < 50 ng/mL and > 5000 ng/mL were obtained by extrapolation of de calibration curves. 316 
 317 
3.3. Correlation results 318 
The genetic and toxicological results were correlated. Cases where was not possible to 319 
confirm the presence of at least one of the metabolites were excluded, remaining a total 320 
of 73 cases. The concentration ratio of TMD and its metabolites was plotted in a 321 
boxplot graphic with a decimal logarithmic scale and the samples were grouped in two 322 
categories according to the genotypes: PM and others. A third group of cases with 323 
positive result to inhibitors compounds, such as fluoxetine, paroxetine, sertraline, 324 
citalopram, ticlopidine and methadone [25,38,39] was also plotted (INIB). Graphics are 325 
presented in Fig. 1. 326 
 327 
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Fig. 1. Distribution of the concentration ratios tramadol/O-demethyltramadol (graphic 1), 330 
tramadol/N-demethyltramadol (graphic 2) and N-demethyltramadol/O-demethyltramadol 331 
(graphic 3) according to the poor-metabolizer predicted phenotype (PM; n=6), the cases that 332 
were positive for substances that are considered enzymatic inhibitors (INIB; n=10)) and the 333 
other cases (n=57).  334 
 335 
The metabolic ratios TMD/ODT or TMD/NDT used by other authors [7,9], as well as 336 
the concentration ratio NDT/ODT were tested. The best correlation was obtained using 337 
NDT/ODT ratio, as is shown in the graphics presented in Fig. 1. This observation can 338 
be explained by the complementarity of the two tramadol metabolic pathways [1,7,10]. 339 
In the presence of high substrate concentrations, low CYP2D6 concentrations or when 340 
this enzyme is inhibited, a metabolic switch in favor of enhanced N-demethylation can 341 
be observed. On the other hand, the possible involvement of CYP2D6 in the elimination 342 
process of NDT may explain the increase in its concentration. So, in these cases the 343 
ratio between the two metabolites will be higher, allowing to differentiate the PM 344 
phenotype and the possible presence of a CYP2D6 inhibitor. 345 
 346 
Using the concentration ratio NDT/ODT, the poor metabolizers (PM) are completely 347 
separated from the others (INIB and Others), with a NDT/ODT concentration ratio 348 
1 2 
3 
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above 7. The INIB group has a wide concentration ratio interval, but more than 3 349 
quarters are between 2,5 and 7. In these cases, regardless of genotype, the interaction of 350 
the inhibitors leads to a different metabolic behavior. These results are in accordance 351 
with other previous studies [15,38,40,41]. The medians of the groups were statistically 352 
compared using a Mann-Whitney test with a level of significance of 0.05 and proved to 353 
be significantly different using the NDT/ODT ratio. 354 
 355 
In post-mortem cases, the information about the administration is oftentimes unknown, 356 
like the time, dosage, route and the time until death [9]. The concentration range is very 357 
wide for both the parent compound and the metabolites and is not correct to compare it 358 
with the results obtained in clinical studies. A high TMD/ODT does not necessarily 359 
means that there is a deficient metabolization. Many factors can explain it, like co-360 
medication, existence of pathologies, or if the death occurred right after the 361 
administration. NDT/ODT ratio can be useful to reduce the impact of those unknown 362 
variables, as the degree of metabolization at the time of death. Further evaluation of 363 
these data might be important and should be considered in future studies. 364 
3.4.Case Results 365 
In this study, six individuals were found to be poor-metabolizers (PM). All the available 366 
information concerning these six cases is presented in the Table 6.  367 
 368 
Table 6. Case information: Age, gender, probable cause of death, toxicological findings and 369 
genotype of the 6 PM cases. 370 
CASE age gender Probable 
cause of 
death  
TMD 
 
NDT 
(ng/mL) 
ODT Other 
substances 
(ng/mL) 
Ethanol 
(g/L) 
GEN 
1 66 male Unknown 1137 1479 161 Pethidine (12) 
Sertraline (212) 
Benzodiazepines 
(< therap) 
negative *4/*3 
2 64 male Unknown > 5000 1338 167 Ticlopidine (401) 
Trazodone (156) 
Bromazepam (54) 
Flurazepam (291) 
0.13 *4/*4 
3 71 male Natural 
(Neoplasy) 
2130 1502 50 negative negative *4/*4 
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4 71 male Accident 
(traumatic) 
528 221 30 negative negative *4/*4 
5 55 male Unknown 205 103 <25 negative negative *4/*4 
6 83 male Suicide 
(hanging) 
147 262 <25 Paroxetine (160) 
Alprazolam (6) 
negative *4/*4 
(in the table: TMD, NDT and ODT are tramadol, N-desmethyltramadol 371 
 and O-desmethyltramadol concentrations; GEN is the genotype) 372 
 373 
The first three cases have tramadol concentrations higher than the therapeutic range 374 
according to reference tables [36,37] but the ODT concentrations are comparatively 375 
low, considering the data published by Grond et Sablotzki and Stamer et al [1, 11, 12]. 376 
Namely in the case number 3 the ODT concentration is comparable to the obtained as a 377 
therapeutic concentration in the pharmacokinetics studies. In this particular case, the 378 
individual was a cancer patient. The absence of a functional genetic variant for CYP2D6 379 
can explain the concentrations found in post-mortem peripherical blood. The higher 380 
concentration of tramadol may be due to accumulation or to an increment of the dosage, 381 
which can be related with a decrease in the opioid analgesic effect associated with the 382 
lower ODT concentration. However, we cannot exclude the possibility of the lack of 383 
analgesic effect be due to the development of tolerance in a chronic user. Only one pill 384 
was found at the stomach content and the cause of death was determined as natural. 385 
 386 
Predicting the analgesic effect of tramadol based on the pharmacogenetics results is 387 
tempting but there are multiple factors, some of them still unknown, that can influence 388 
the interpretation [42,43]. Additional fundamental research and collection of routine 389 
data is still needed before using pharmacogenetics results as evidence in court. 390 
However, in particular post-mortem cases, these approaches, together with all the 391 
autopsy findings and clinical information, can be very useful in the investigation of 392 
cause of death. 393 
 394 
4. Conclusions 395 
This study proved that Sanger sequencing methodology can be successfully applied to 396 
the detection of genetic polymorphisms at CYP2D6 in post-mortem blood samples. The 397 
method proved to be specific, accurate, with a good precision and limit of detection for 398 
the null variants analyzed.  399 
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The results showed a good correlation between the PM genotype and the toxicology 400 
results of the tramadol metabolic ratio NDT/ODT, appearing to be an alternative 401 
parameter in the evaluation of the degree of metabolization of tramadol in post-mortem 402 
cases.  403 
The presence of enzymatic inhibitors affects significantly the degree of metabolization, 404 
which can be seen in the results obtained. By this reason, is very important to include 405 
that compounds in the toxicology screening.  406 
The detection of allelic variants described as non-functional can be useful to explain 407 
some circumstances of death in the study of tramadol positive cases and the results 408 
obtained demonstrate the importance of this genetic tool to forensic toxicology and 409 
pathology. 410 
Sanger sequencing methodology applied in this study can also be applied to cases with 411 
other substances with the same metabolic pathway (CYP2D6), such as codeine, 412 
antidepressants and neuroleptics. 413 
 414 
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We would like to thank both reviewers for the deep appreciation of our manuscript and for all the 
suggestions. We tried to fulfill all the requirements and we will answer point-by point to the comments 
 
Reviewer #1:  
 
1. The introduction of this manuscript oversimplifies the metabolism and pharmacological 
properties of tramadol. The metabolism of tramadol is complex and mediated by several 
polymorphic cytochrome P450 enzymes [Gong Li et al. Pharmacogenetics and genomics 
(2014)].   
 
* Secondly, tramadol analgesia is mediated not only by the polymorphic mu opioid receptor but 
also through modulation of norepeniphrine ad serotonergic re-uptake.   
A: I have reformulated the introduction as suggested. 
 
* Thirdly, tramadol is not always given in controlled doses (as stated), but commonly prescribed 
in outpatient settings.  Therefore, the assumption that higher than expected tramadol doses would 
arise from malpractice or neglect is short-sighted and should probably be removed from the 
manuscript althogether as it is outside the scope of this work. 
A: Removed as suggested. 
 
2. Please provide a reference to support the statement (page 3) that PM of tramadol have reduced 
analgesic effects with tramadol and reduced adverse effects with tramadol. 
A: Done. 
 
3. The postmortem concentrations should not, in general, be compared to those in clinical 
studies/therapeutic studies.  Please discuss at length the various issues with postmortem findings 
(post-mortem redistribution, variances in drug collection sites (femoral blood, etc), death 
interval) as they pertain to the population in this study, and as they pertain to tramadol 
specifically. 
 A: We have added the information required. 
 
4. The methods section should clearly state which concomitant medications were considered in this 
study as CYP2D6 substrates. Furthermore, not all CYP2D6 substrates are "inhibitors".  Please 
refer to the page by David Flockhart in Indiana University for correct classification of 
medication as CYP2D6 substrate or inhibitor. 
A: The analytical method has the most common medication, including anti-depressants, antipsychotic and 
other opioids. For the INIB group we have focused in the substances that are reported as inhibitors (also 
in the Flockhart chart). The outliers of the “others” group on the NDT/ODT graphic are, curiously, 
*Revision Notes (Response to Reviewers)
positive for compounds that are also substrates of CYP2D6, as venlafaxine and nortriptiline. Done as 
suggested. 
 
5. There are over 100 allelic variants of CYP2D6.  In this study, the author's method only 
categorizes 4 of these variants.  The authors then subscribe individuals to either poor, 
intermediate, or extensive metabolizers based on only 4 variants and make several assumptions 
on their tested population to rationalize this approach.  As their testing approach is not the gold 
standard in pharmacogenetic testing, given its limited scope of testing, they need to compare 
their methodology with a platform that tests for the majority of CYp2D6 alleles in order to 
justify these assumptions.  A false positive and false negative rate of attributing an individual to 
the poor metabolizer phenotype based on only 4 variants needs to be provided. 
 
A:  We have clarified in the manuscript the aims of our work. 
The focus was to detect the PM. We have tried to explain better the exceptions. We changed also the 
assignment of the genotypes based in the variants searched to restrict it to the PM. 
On the other hand, we described in more detail the validation of the method. It is not possible for us to 
compare our results with other methodology as suggested, but we had used reference materials to evaluate 
the accuracy of the method. 
 
 
We would like to thank both reviewers for the deep appreciation of our manuscript and for all the 
suggestions. We tried to fulfill all the requirements and we will answer point-by point to the comments 
 
Reviewer #2:  
 
1. The present manuscript describes a Sanger sequencing method for detection of some CYP2D6 
polymorphisms causing a reduced or absent enzyme function, as well as a GC/MS method for 
the quantitation of tramadol, O-desmethyltramadol and N-desmethyltramadol. The methods were 
applied to 100 tramadol positive post-mortem samples. The purpose of doing that is however not 
clearly stated. Several papers on CYP2D6 sequencing methods and quantitative tramadol 
methods have been published previously. Furthermore, many of those are better described in 
terms of validation and performance and are using techniques able to detect also the CYP2D6 
ultra-rapid metabolizers and quantifying the enantiomers of tramadol and its metabolites. If the 
authors clearly state the aim of identifying poor metabolizers and further describe and discuss 
the six cases being poor metabolizers the present manuscript could however add on to the current 
knowledge within this field.  
A:  We have clarified in the manuscript the aims of our work. 
 
2. Abstract: 
* "A Sanger sequencing methodology was developed for the detection of genetic variants that 
cause absence of CYP2D6 activity, such as *3, *4, *6, *8, *10 and *12 alleles". As mentioned 
later in the manuscript *10 causes a decreased function of the enzyme, not a total absence. 
Consider to reformulate, for example "…genetic variants that cause absent or reduced CYP2D6 
activity". 
A: Done. 
* Why is not all alleles possible to identify with the present method mentioned?  
A: The amplification of the entire gene is very difficult (> 5000pb), specially in post-mortem samples 
with high degradation index. On the other hand, Sanger sequencing only allows the analysis of amplicons 
with a maximum of 1000 pb. To detect copy number variation is necessary to use other methods, with 
other equipments such as real-time PCR or platforms as AmpliChip CYP450 test from Roche. The 
method that we have used is simple, rapid, low cost and available in forensic genetics labs and can detect 
the main variants. We had clarified it on the manuscript as required. 
 
3. Introduction: 
* The aim of the study is not clearly stated. Why was the study conducted? What was the 
research question? Any hypothesis?  
A:  We have clarified in the manuscript the aims and scope of our work. 
 
*Revision Notes (Response to Reviewers)
* In the first paragraph it is written that "The information about therapeutic concentrations of 
ODT is scarce". There are however several publications covering both tramadol and ODT 
concentrations.  
A: The sentence was removed. There are several publications with clinical studies but the toxic or lethal 
concentrations aren’t well defined, to our knowledge. 
* UMs are usually referred to as ultra-rapid metabolizers but in this paper the term ultra-
metabolizers are used instead. Consider changing that.  
A: Changed 
* I also suggest that explanations of abbreviations, for example "poor metabolizer (PM)", are 
given the first time the word is written. Subsequently only the abbreviation is used.  
A: Changed 
 
4. Materials and methods: 
* If the toxicological analysis has been published previously a reference referring to that 
publication could be added to section 2.2. If there is no previous publication the sample 
preparation and validation could be further described. The validation parameters investigated are 
given but no information on how the experiments were conducted. What chemicals, reagents and 
reference compounds were used? What quality control levels were used? How many replicates 
were utilized? What kind of blank blood was used? What were the predetermined acceptance 
criteria for each validation parameter? Please clarify in the manuscript. 
* It is also important that results are given for all the validation parameters investigated, and they 
could with advantage be given in the results and discussion section.  
* It is stated that the coefficient of variation is under 11% for the three compounds. Clarify what 
parameters that are referred to.  
* Was dilution integrity part of the validation? Since calibration ranges between 0.05-1 mg/L 
and some samples have significantly higher concentrations I assume some dilution was made? 
Please clarify in the manuscript.  
A: we described in more detail the validation of the method.  
* What transitions were used in SIM mode? Add those to the manuscript.  
A: added as requested. 
 
* The two first comments for this section are applicable also to the validation of the sequencing 
method. There is no information on how the validation experiments were conducted and results 
are scarce. "The quality of the sequences was considered good", in terms of what? Accuracy is 
an especially important parameter when it comes to Sanger sequencing; how was the accuracy 
experiment conducted and what was the result of it? Please describe in the manuscript. 
A: we described in more detail the validation of the method.  
 
* Should pb be bp instead, bp for base pairs?  
A: Changed 
* Which polymorphisms were used for the identification of allele *8, *12, *14, *15, *40 etc., 
mentioned on page 5? Add those to the manuscript.  
A: Done 
* The thermocycling conditions used for each fragment could be described in the manuscript. 
A: Done 
 
5. Results and discussion: 
* The first sentence on page 6 is in my opinion not necessary.  
A: Removed 
* Check the maximum concentration for NDT in table 1, should it be 5889? 
A: Corrected 
* It does not emerge from table 1 that 27 cases had metabolite concentrations below the 
detection limit (is the limit of detection and the limit of quantitation the same?), as it does in the 
text. Consider if it should since minimum values for the metabolites are presented in the table, 
and the table text says descriptive statistics for all the 100 cases.  
A: Corrected.  
Values < 50 ng/mL and > 5000 ng/mL were obtained by extrapolation of de calibration curves. 
* Concerning the first and second sentence in section 3.2: What was the degradation index of the 
three samples that failed amplification in comparison to the degradation index of the other 
samples? That information would be of interest to add to the manuscript. 
A: added as requested. 
as suggested * If it is desirable to shorten the manuscript figure 1 and 2 could be deleted since 
the information is given in the text as well.  
A: Removed 
* In figure 2 and table 2 the text implies results for all the 100 post-mortem samples. However, 
since 3 samples failed amplification the results are only for 97 samples, right? Prevalences in 
table 2 as well as allele frequencies in figure 2 need to be slightly adjusted in case of calculating 
with 100 samples, which seems to be the case since the sum of prevalences in table 2 should be 
100% but is only 97%.  
A: Corrected.  
* The allele frequency of the null allele *5 (which was not searched for) is higher than that of *3 
and *6 (which was searched for) in a Caucasian population. Therefore consider to reformulate 
the following sentences on page 7 "All the alleles that hadn´t any variant in the studied 
fragments were considered as wild type. This assumption was considered acceptable because the 
prevalence of the other null alleles that weren´t searched for is very low in Caucasian 
population".  
A: The sentence was removed and we have tried to explain better the exceptions, focusing in the 
identification of the PM, which is the main purpose of the study. 
* In section 3.2 it is written "Since this method is not able to detect CNV events, the ultra-
metabolizers were included in the group of EM. This assumption was considered acceptable 
once the final objective of the present work was to detect the PM". What was the purpose of 
constructing figure 3 if only PMs were important to find? Consider to reformulate.  
A: We changed the assignment of the genotypes based in the variants searched to restrict it to the PM. 
Thank you for your suggestions. 
* A further description of the INIB group would be valuable. Were those cases PM, IM or EM? 
What was the concentrations of the inhibitors? To be able to draw conclusions about the 
significance of the inhibitors a comparison between for example EMs with and without 
inhibitors seems more valuable than putting all cases with inhibitors in one group, regardless of 
genotype.  
A: Since we had focused in the PM cases, we removed the EM and IM assignment. On the other hand, 
and unfortunately, the available information of the cases is scarce. We were not able to do this. 
* Table 3 is in my opinion not necessary. It would be more interesting to compare all the 
measured values for each group, than just comparing medians between groups. Statistically 
significant differences based on all measured values for each group could be indicated in figure 
3, a separate table is not necessary. The number of individuals that are given in table 3 could be 
given in the text below figure 3.  
A: Done as suggested. 
* Abbreviations are not explained in the text below figure 3 which would be good.    
A: corrected as suggested. 
* Why does the authors conclude that the NDT/ODT ratio is a better measure of TMD to ODT 
metabolism than the TMD/ODT ratio? The correlation seemed better for the NDT/ODT ratio, 
yes, although other factors than the CYP2D6 genotype might affect this ratio. A discussion 
concerning the impact of CYP2B6 and CYP3A4 genotype for the formation of NDT would be 
meaningful. If the authors think that the correlation between the TMD/ODT ratio and CYP2D6 
genotype was less than expected a discussion concerning reasons for this would be highly 
valuable. Could for example the inability of the sequencing method to detect allele *5 and 
multiple copies of the gene have had an impact on the results? Or could the classification into 
IMs and EMs have had an impact? The present classification is not wrong although according to 
other definitions EMs have two functional alleles. The present EM group includes individuals 
with both one, two and multiple copies of CYP2D6 alleles.   
A: We have tried to explain it better, especially for post-mortem cases. 
* The information in table 4 is interesting, as well as the measured concentrations in table 5, 
although the concentration unit must be given in table 5. This information could however be 
compiled in one table, while DNA-concentration, degradation index and polymorphisms are left 
out. The important thing is that all individuals are PMs and that information is given in the table 
text.  
A: Done as suggested. 
* The results of table 4 and 5 are only discussed with a few sentences on page 11, saying that in 
three cases the tramadol concentration was higher than the therapeutic range but ODT 
concentrations were acceptable. What does that mean, what are the conclusions drawn? Case 2 
and 3 have "unknown" and "natural" stated as the cause of death, respectively, in spite of high 
tramadol concentrations. Was the tramadol concentrations not considered toxic (because of low 
ODT concentrations)? What were the circumstances of death? Any comments regarding the 
other cases? Please discuss the results in more detail.  
* What substances were included in the toxicological screening? It could be interesting to 
describe case 3,4 and 5 (without other substances present) in more detail.  
* It could perhaps be of interest to show the concentrations and CYP2D6 genotypes for the 10 
intoxication cases mentioned in section 2.1.  
A: Done as suggested, although we cannot discuss better the results because of the lack of information. 
The study of the autopsy results of these cases together with the pathologists would be indeed very 
interesting but it was not possible yet. 
 
6. Conclusions: 
* "The Sanger sequencing method proved to be specific, accurate, with a good precision and 
limit of detection". As mentioned previously results for all validation parameters are not 
presented in the manuscript, for what reason it is difficult for the reader to be able to draw the 
same conclusion.  
A: We have reformulated the manuscript and included the validation parameters. 
* "The results of genotypes showed a good correlation with toxicology results of the tramadol 
metabolic ratio NDT/ODT, appearing to be a better parameter to know the degree of 
metabolization of TMD to ODT, than the usual metabolic ratio as TMD/ODT". See also the 
comments above in the "results and discussion" section. In my opinion this is not a correct 
conclusion.  
A: We have reformulated the results and discussion and also the conclusions in the manuscript.  
* "The presence of enzymatic inhibitors affects significantly the degree of metabolization" 
See also the comments above in the "results and discussion" section. It is known that some drugs 
acts as inhibitors of CYP2D6 and therefore affect the metabolism of tramadol. In my opinion it 
is however not satisfactory shown in this manuscript.  
A: We have reformulated the conclusions in the manuscript. 
* "The detection of allelic variants described as non-functional were useful to explain some 
circumstances of death in the study of tramadol positive cases and demonstrate the importance of 
this genetic tool to forensic toxicology and pathology".  What circumstances were clarified in 
this study? A more profound discussion regarding the results is desirable. 
A: As said above, it was not possible yet. Nevertheless, the cases number 1 and 3 can be good examples 
of the future applications of this approach.   
 
7. References: 
* Is reference 8, 12 and 13 complete? Where can one find them? 
A: Corrected 
* Where is reference 19 published? 
A: Corrected 
* I am not sure if user guides (reference 20 in this case) are appropriate to refer to in the 
reference list? 
A: Removed 
 
